Re Aim Therapeutics is redefining how autoimmune diseases are treated by selectively depleting the pathogenic T cell subsets that drive chronic inflammation, autoimmunity and disease progression. By integrating human pathway signatures and transcription factor-linked membrane targets, we pinpoint the precise T cell coordinating and maintaining the autoimmune responses. By drugging precise target epitopes in their functional state and within the relevant disease context, we achieve a level of selectivity that conventional expression profiling and engineering approaches cannot reach. Our mission is to deliver functional cures across a broad spectrum of autoimmune conditions. We are a team with exceptional antibody discovery and development expertise, world‑class scientific advisors, and committed investors, all aligned around rigorous execution and transformative impact.